OncoMatch/Clinical Trials/NCT03624244
Evaluation of Clinical Impact of Interruption VS Maintenance of AI in Patients With Locally Advanced/ Metastatic Low Grade Endometrial Stromal Sarcoma (LGESS)
Is NCT03624244 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Aromatase Inhibitors for low grade endometrial stromal sarcoma.
Treatment: Aromatase Inhibitors — The primary objective is to compare the progression-free survival (PFS) between aromatase inhibitors interruption and aromatase inhibitors maintenance strategies in patients with a locally advanced or metastatic Low Grade Endometrial Stromal Sarcoma (LGESS).
Check if I qualifyExtracted eligibility criteria
Cancer type
Sarcoma
Disease stage
Grade: low grade
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: aromatase inhibitor (anastrozole, exemestane, letrozole) — initiated for at least 24 months (no residual/non-measurable disease) OR at least 36 months (measurable disease) prior to randomisation; disease must be controlled (objective response or stable disease) at randomisation
Treatment with aromatase inhibitors (Anastrozole or Exemestane or Letrozole ) initiated either: for at least 24 months (in patients with no residual disease or non-measurable disease at the last AI initiation) OR for at least 36 months (in patients with measurable disease at the last AI initiation); Disease must be controlled at the time of the randomisation (objective response or stable disease) by the aromatase inhibitor initiated either for at least 24 or 36 months
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify